These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 18425336

  • 1. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
    Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M.
    Int J Oncol; 2008 May; 32(5):1091-6. PubMed ID: 18425336
    [Abstract] [Full Text] [Related]

  • 2. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.
    Clin Cancer Res; 2005 Sep 01; 11(17):6212-7. PubMed ID: 16144923
    [Abstract] [Full Text] [Related]

  • 3. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):493-500. PubMed ID: 19960344
    [Abstract] [Full Text] [Related]

  • 4. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 5. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 6. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 20; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N, Lenz HJ.
    Clin Adv Hematol Oncol; 2003 Mar 20; 1(3):162-6. PubMed ID: 16224397
    [Abstract] [Full Text] [Related]

  • 8. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.
    Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.
    Cancer Chemother Pharmacol; 2011 Oct 20; 68(4):935-44. PubMed ID: 21298384
    [Abstract] [Full Text] [Related]

  • 9. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 20; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 10. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 20; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 11. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, Ma Y, Wuren T, Ge RL.
    J Cancer Res Ther; 2013 Jan 20; 9(3):410-5. PubMed ID: 24125975
    [Abstract] [Full Text] [Related]

  • 12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 20; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 13. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H, Hayashi K, Uchida K, Nakajima G, Hatori T, Danenberg KD, Danenberg PV, Yamamoto M.
    Cancer Chemother Pharmacol; 2008 Dec 20; 63(1):85-9. PubMed ID: 18309485
    [Abstract] [Full Text] [Related]

  • 14. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
    Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A, Cufer T.
    Eur J Cancer; 2012 Dec 20; 48(18):3378-85. PubMed ID: 22795264
    [Abstract] [Full Text] [Related]

  • 15. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH.
    Clin Cancer Res; 2005 Mar 15; 11(6):2215-21. PubMed ID: 15788669
    [Abstract] [Full Text] [Related]

  • 16. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 17. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 10; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 18. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
    Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL.
    Jpn J Clin Oncol; 2010 Apr 10; 40(4):286-93. PubMed ID: 20085902
    [Abstract] [Full Text] [Related]

  • 19. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 20. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.